Modality
ASO
MOA
ALKi
Target
Nectin-4
Pathway
T-cell
NB
Development Pipeline
Preclinical
~Apr 2014
→ ~Jul 2015
Phase 1
~Oct 2015
→ ~Jan 2017
Phase 2
Apr 2017
→ Apr 2031
Phase 2Current
NCT06844499
2,659 pts·NB
2023-03→2031-04·Active
NCT08132899
1,472 pts·NB
2017-04→2028-07·Not yet recruiting
4,131 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-07-272.3y awayPh2 Data· NB
2031-04-245.1y awayPh2 Data· NB
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2
Not yet…
P2
Active
Catalysts
Ph2 Data
2028-07-27 · 2.3y away
NB
Ph2 Data
2031-04-24 · 5.1y away
NB
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06844499 | Phase 2 | NB | Active | 2659 | ACR20 |
| NCT08132899 | Phase 2 | NB | Not yet recr... | 1472 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| ALN-3284 | Alnylam | Phase 2/3 | CDK2 |